Cargando…

Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an extremely challenging disease with a high mortality rate and a short overall survival time. The poor prognosis can be explained by aggressive tumor growth, late diagnosis, and therapy resistance. Consistent efforts have been made focusing on early tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Q., Maier, S. H., Li, P., Peterhansl, J., Belka, C., Mayerle, J., Mahajan, U. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409417/ https://www.ncbi.nlm.nih.gov/pubmed/32758252 http://dx.doi.org/10.1186/s13014-020-01624-1

Ejemplares similares

Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma
por: Liu, An‐Dong, et al.
Publicado: (2021)

A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma
por: Clawson, Gary A., et al.
Publicado: (2017)

Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
por: Orth, Michael, et al.
Publicado: (2019)

Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers
por: El Kaoutari, Abdessamad, et al.
Publicado: (2023)

Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene
por: Schmohl, Kathrin A., et al.
Publicado: (2017)

Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
por: Osei-Bordom, Daniel C., et al.
Publicado: (2022)

Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma
por: Champanhac, Carole, et al.
Publicado: (2015)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Super-enhancers: novel target for pancreatic ductal adenocarcinoma
por: Ghosh, Chandrayee, et al.
Publicado: (2019)

Splice variants as novel targets in pancreatic ductal adenocarcinoma
por: Wang, Jun, et al.
Publicado: (2017)

Aptamer Nanomaterials for Ovarian Cancer Target Theranostics
por: Zhao, Jing, et al.
Publicado: (2022)

Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Mahajan, Ujjwal Mukund, et al.
Publicado: (2021)

DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition
por: Wu, Xiaoqiu, et al.
Publicado: (2015)

Metabolic biomarkers for the differential diagnosis of pancreatic ductal adenocarcinoma vs. chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2014)

Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)

Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
por: Cruz-Monserrate, Zobeida, et al.
Publicado: (2014)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
por: Sato, Norihiro, et al.
Publicado: (2016)

Targeting dendritic cells in pancreatic ductal adenocarcinoma
por: Deicher, Anton, et al.
Publicado: (2018)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

Schlafen 5 as a Novel Therapeutic Target in Pancreatic Ductal Adenocarcinoma
por: Fischietti, Mariafausta, et al.
Publicado: (2021)

Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo
por: Yoon, Sorah, et al.
Publicado: (2016)

Aptamer‐based biosensors and application in tumor theranostics
por: Mo, Tong, et al.
Publicado: (2021)

Radiolabelled Aptamers for Theranostic Treatment of Cancer
por: Khalid, Umair, et al.
Publicado: (2018)

MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)
por: Pavic, M., et al.
Publicado: (2022)

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma
por: Li, Junjie, et al.
Publicado: (2016)

Aptamer-guided extracellular vesicle theranostics in oncology
por: Tran, Phuong H-L, et al.
Publicado: (2020)

Targeted Nanoparticles for Imaging Incipient Pancreatic Ductal Adenocarcinoma
por: Kelly, Kimberly A, et al.
Publicado: (2008)

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2020)

Key drug-targeting genes in pancreatic ductal adenocarcinoma
por: Sakharkar, Meena Kishore, et al.
Publicado: (2021)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma
por: Karimnia, Vida, et al.
Publicado: (2021)

Engineered Aptamers for Enhanced COVID-19 Theranostics
por: Acquah, Caleb, et al.
Publicado: (2021)

Aptamer-engineered (nano)materials for theranostic applications
por: Rabiee, Navid, et al.
Publicado: (2023)

Oral mycobiota and pancreatic ductal adenocarcinoma
por: Wei, Ailin, et al.
Publicado: (2022)

Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening
por: Geyer, Marlene, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cciiuho03a3p1od14oh5lv720e